[go: up one dir, main page]

WO2018175633A1 - Procédés d'induction de réponses immunitaires antipaludiques et compositions associées - Google Patents

Procédés d'induction de réponses immunitaires antipaludiques et compositions associées Download PDF

Info

Publication number
WO2018175633A1
WO2018175633A1 PCT/US2018/023628 US2018023628W WO2018175633A1 WO 2018175633 A1 WO2018175633 A1 WO 2018175633A1 US 2018023628 W US2018023628 W US 2018023628W WO 2018175633 A1 WO2018175633 A1 WO 2018175633A1
Authority
WO
WIPO (PCT)
Prior art keywords
hepcidin
composition
seq
mini
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/023628
Other languages
English (en)
Inventor
Lakhmir Chawla
Sanjeev Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City St Georges University of London
La Jolla Pharmaceutical Co
Original Assignee
St Georges Hospital Medical School
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Georges Hospital Medical School, La Jolla Pharmaceutical Co filed Critical St Georges Hospital Medical School
Publication of WO2018175633A1 publication Critical patent/WO2018175633A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the malaria vaccine is administered to the subject and, after a period of time, the chemoprophylaxis is administered to the subject.
  • the chemoprophylaxis is administered to a subject who develops malaria after treatment with the vaccine (e.g., to avoid treating subjects who successfully develop an immune response and/or eradicate the administered Plasmodium falciparum).
  • the hepcidin or mini-hepcidin and the malaria vaccine are in the same composition.
  • the hepcidin or mini-hepcidin and the malaria vaccine are in separate compositions and may be administered at the same time or sequentially.
  • A10 is L-Cys, L-Ser, L-Ala, D-Cys, D-Ser, or D-Ala;
  • the malaria vaccine further comprises an adjuvant and a pharmaceutically acceptable carrier.
  • adjuvant refers to an agent that stimulates the immune system and increases the response to a vaccine.
  • Vaccine adjuvants are well-known to those of skill in the art.
  • carrier refers to an ingredient other than the active component(s) in a formulation. The choice of carrier will to a large extent depend on factors such as the particular mode of administration or application, the effect of the carrier on solubility and stability, and the nature of the dosage form. Pharmaceutically acceptable carriers for polypeptide antigens are well known in the art.
  • the subject is further administered a malarial chemoprophylaxis (e.g., chloroquine, tetracycline, proguanil, chlorproguanil, pyronaridine, lumefantrinel, mefloquine, dapsone, atovaquone, artesunate and artemisinin).
  • the malaria vaccine may comprise a radiation attenuated PfSPZ.
  • the composition disclosed herein may be administered at the same time or sequentially.
  • the malaria vaccine may comprise a chemoattenuated PfSPZ vaccine.
  • materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydrox
  • Treating" a disease in a subject or “treating” a subject having a disease refers to subjecting the subject to a pharmaceutical treatment, e.g., the administration of a drug, such that at least one symptom of the disease is decreased or prevented from worsening.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes et des compositions pour vacciner des sujets contre la malaria, ou sinon favoriser le développement d'une réponse immunitaire contre Plasmodium falciparum. Selon certains aspects, l'invention concerne des compositions comprenant un vaccin antipaludique et de l'hepcidine ou une mini-hepcidine.
PCT/US2018/023628 2017-03-22 2018-03-21 Procédés d'induction de réponses immunitaires antipaludiques et compositions associées Ceased WO2018175633A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762474894P 2017-03-22 2017-03-22
US62/474,894 2017-03-22

Publications (1)

Publication Number Publication Date
WO2018175633A1 true WO2018175633A1 (fr) 2018-09-27

Family

ID=63584705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/023628 Ceased WO2018175633A1 (fr) 2017-03-22 2018-03-21 Procédés d'induction de réponses immunitaires antipaludiques et compositions associées

Country Status (1)

Country Link
WO (1) WO2018175633A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4288055A4 (fr) * 2021-02-05 2024-12-18 Merck Sharp & Dohme LLC <smallcaps/>? ? ?plasmodium? ? ? ? ?chimiovaccination contre une infection paravec des inhibiteurs sélectifs de la plasmepsine x

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065815A2 (fr) * 2008-12-05 2010-06-10 The Regents Of The University Of California Mini peptides d'hépcidine et leurs procédés d'utilisation
WO2010083111A1 (fr) * 2009-01-16 2010-07-22 Sanaria Inc. Plasmodium purifié et compositions de vaccin
WO2015157283A1 (fr) * 2014-04-07 2015-10-15 Merganser Biotech Llc Peptides mimétiques d'hepcidine et utilisations desdits peptides
WO2017120419A1 (fr) * 2016-01-08 2017-07-13 La Jolla Pharmaceutial Company Procédés d'administration d'hepcidine
WO2018048944A1 (fr) * 2016-09-06 2018-03-15 La Jolla Pharmceutical Company Méthodes de traitement d'une surcharge en fer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065815A2 (fr) * 2008-12-05 2010-06-10 The Regents Of The University Of California Mini peptides d'hépcidine et leurs procédés d'utilisation
WO2010083111A1 (fr) * 2009-01-16 2010-07-22 Sanaria Inc. Plasmodium purifié et compositions de vaccin
WO2015157283A1 (fr) * 2014-04-07 2015-10-15 Merganser Biotech Llc Peptides mimétiques d'hepcidine et utilisations desdits peptides
WO2017120419A1 (fr) * 2016-01-08 2017-07-13 La Jolla Pharmaceutial Company Procédés d'administration d'hepcidine
WO2018048944A1 (fr) * 2016-09-06 2018-03-15 La Jolla Pharmceutical Company Méthodes de traitement d'une surcharge en fer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PORTUGAL , S. ET AL.: "Host-mediated regulation of superinfection in malaria", NATURE MEDICINE, vol. 17, no. 6, 15 May 2011 (2011-05-15), pages 732 - 737, XP055544040, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200394/pdf/nihms330622.pdf> [retrieved on 20180517] *
PRENTICE, ANDREW M. ET AL.: "Iron and malaria interactions: research needs from basic science to global policy", ADVANCES IN NUTRITION, vol. 3.4, 6 July 2012 (2012-07-06), pages 583 - 591, XP055544038, Retrieved from the Internet <URL:https://academic.oup.com/advances/article/3/4/583/4591520><doi:10.3945/an.111.001230> [retrieved on 20180517] *
WANG, HAI-ZHEN ET AL.: "Hepcidin is regulated during blood-stage malaria and plays a protective role in malaria infection", JOURNAL OF IMMUNOLOGY, 14 November 2011 (2011-11-14), pages 6410 - 6416, XP055494691, Retrieved from the Internet <URL:https://pdfs.semanticscholar.org/1362/3fb3771277e05fb649155cfcab4af6fdlc81.pdf> [retrieved on 20180517] *
YA-QUN, F. A. N. G. ET AL.: "In vivo antimalarial activity of synthetic hepcidin against Plasmodium berghei in mice", CHINESE JOURNAL OF NATURAL MEDICINES, vol. 15.3, 20 March 2017 (2017-03-20), pages 161 - 167, XP029978743, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S1875536417300328> [retrieved on 20180521] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4288055A4 (fr) * 2021-02-05 2024-12-18 Merck Sharp & Dohme LLC <smallcaps/>? ? ?plasmodium? ? ? ? ?chimiovaccination contre une infection paravec des inhibiteurs sélectifs de la plasmepsine x

Similar Documents

Publication Publication Date Title
CN103260641B (zh) 疟疾的治疗和预防
SK282438B6 (sk) Vakcínový prostriedok obsahujúci antigény proti malárii
KR20150119110A (ko) 에이메리아에 대한 면역 반응을 증진시키거나, 에이메리아 감염을 제한하는 조성물 및 방법
JP2008546831A (ja) 真菌感染及び／又は原生生物感染の治療
WO2006127715A1 (fr) Peptides antimicrobiens
CA2337754C (fr) Vaccin anti-paludeen recombinant multivalent dirige contre plasmodium falciparum
US20120328645A1 (en) Malaria Vaccines
US20220054619A1 (en) Lipopeptide building blocks and synthetic virus-like particles
WO2018062217A1 (fr) Vaccin contre le virus ebola
CN86100428A (zh) 疟疾疫苗的制备方法
WO1990000402A1 (fr) Vaccin synthetique contre la malaria de p. de falciparum
US7198791B2 (en) Compositions and methods for the generation of protective immune responses against malaria
WO2018175633A1 (fr) Procédés d&#39;induction de réponses immunitaires antipaludiques et compositions associées
US7749519B2 (en) Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax
MXPA01006548A (es) Gen de quimerico que codifica los determinantes antigenicos de cuatro proteinas de l. infantum.
US20080213318A1 (en) Malaria MSP-1 C-terminal enhanced subunit vaccine
HUP0200302A2 (en) Malaria vaccine
US7285274B2 (en) Baculovirus produced Plasmodium falciparum vaccine
US10183067B1 (en) TAA/CD4OL composition/vaccine for malaria
WO2016084944A1 (fr) Anticorps artificiel produit à l&#39;aide d&#39;une séquence partielle de protéine énolase issue de plasmodium falciparum, et son procédé de production
US9642901B1 (en) TAA/CD40L vaccine for malaria
WO2020032951A1 (fr) Conjugués d&#39;enzymes antipaludiques, kits les contenant, et procédés de production et d&#39;utilisation associés
US7737262B2 (en) Plasmodium falciparum polypeptides and methods of using same
JP4883839B2 (ja) エル．インファンタム（Ｌ．ｉｎｆａｎｔｕｍ）の４つのタンパク質の抗原決定基をコードするキメラ遺伝子
WO2001085927A1 (fr) Vaccin contre la malaria et methode d&#39;utilisation en fonction d&#39;un nouveau domaine antigenique du plasmodium falciparum

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18770182

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18770182

Country of ref document: EP

Kind code of ref document: A1